With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.103505-54-0,[2,2′-Bipyridine]-6,6′(1H,1’H)-dione,as a common compound, the synthetic route is as follows.,103505-54-0
As shown in scheme 1-b, [Cp*IrCl2]2 (458.4 mg, 0.570 mmol) was reacted with 6,6?-dihydroxy-2,2?-bipyridine ligand (250.0 mg, 1.33 mmol) in methanol solvent (8 mL), a reaction was carried out at 60 C. for 3 hours, and filtration using a glass filter was then carried out to thus give cationic complex A? (yield 74%). Subsequently, cationic complex A? (100.0 mg, 0.170 mmol) was reacted with potassium t-butoxide (38.3 mg, 0.340 mmol) in water (5 mL) at room temperature for 30 minutes while stirring, and a solid thus precipitated was filtered to thus give complex 1 (yield 64%).1H NMR (400 MHz, CD3OD) delta 7.43 (t, J=8 Hz, 2H), 6.92 (d, J=8 Hz, 2H), 6.43 (d, J=8 Hz, 2H), 1.59 (s, 15H). 13C{1H} NMR (125.8 MHz, CD3OD) delta 170.9, 157.3, 139.9, 118.1, 106.9, 88.0, 9.83. Anal. Calcd for C20H23O3N2Ir: C, 45.18; H, 4.36; N, 5.27. Found: C, 45.47; H, 4.01; N, 5.62.
The synthetic route of 103505-54-0 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; Kanto Kagaku Kabushiki Kaisha; Yamaguchi, Ryohei; Fujita, Ken-ichi; (26 pag.)US2016/297844; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI